Gigi T. K. Wong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Gigi T. K. Wong has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Henry Ho-Lung Chan
Laboratory of Experimental Optometry (Neuroscience), School of Optometry, The Hong Kong Polytechnic University, Kowloon, Hong Kong SAR, China
1 shared publication - Jimmy Ka-Wai Cheung
Centre for Myopia Research, School of Optometry, The Hong Kong Polytechnic University, Hong Kong
1 shared publication - Kai Yip Choi
School of Optometry, The Hong Kong Polytechnic University, Hong Kong, China
1 shared publication - Peter H. Li
Centre for Eye and Vision Research (CEVR), 17W Hong Kong Science Park, Hong Kong SAR, China
1 shared publication - Sonia Seen-Hang Chan
Centre for Myopia Research, School of Optometry, The Hong Kong Polytechnic University, Hong Kong SAR, China
1 shared publication - Thomas Chuen Lam
The Hong Kong Polytechnic University Shenzhen Research Institute, Shenzhen, Guangdong, PR China
1 shared publication
Latest Publications
- Open Access
- 29 April 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (9) , 3210
Myopia Control Efficacy and Long-Term Safety of a Novel Orthokeratology Lens (MESOK Study)—A Randomized Controlled Clinical Trial Combining Clinical and Tear Proteomics Data
Myopia control efficacy and long-term safety of the Breath-O-Correct orthokeratology (OK) lens was evaluated in a 2-year randomized, single vision (SV) spectacle lens-controlled, single-blind clinical trial combining clinical and tear proteomics data. A total of 71 children (43 OK, 9.8 ± 1.3 years; 28 SV, 9.5 ± 1.4 years) completed the 2-year study. Axial length (AL), cycloplegic refraction, clinical safety parameters (best-corrected visual acuity, central cornea thickness, corneal endothelial health, ocular surface disease index), and quantitative tear proteomics were evaluated by masked examiners. Mean 2-year-normalized AL elongations in the OK and SV groups differed significantly (p = 0.03) and were 0.37 ± 0.37 mm and 0.60 ± 0.41 mm, respectively. OK-mediated myopia control efficacy was 37.1%. No significant difference was found in clinical safety parameters of both groups (p > 0.10), except for a thinner central corneal thickness in the OK group (p = 0.01). Proteomics revealed modest OK lens-mediated effects on immune response proteins, including an increased abundance of haptoglobin at 6 and 12 months and a decreased abundance of two proteins (neutrophil defensin 3 and histone 4) at 6 months. The changes were further validated using a high-resolution multiple-reaction monitoring (MRMHR) mass spectrometry. In summary, the Breath-O-Correct OK lens significantly reduced AL elongation in schoolchildren without adverse clinical effects or subclinical inflammatory responses.
- 29 April 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (9) , 3210
Open AccessMyopia Control Efficacy and Long-Term Safety of a Novel Orthokeratology Lens (MESOK Study)—A Randomized Controlled Clinical Trial Combining Clinical and Tear Proteomics Data
Myopia control efficacy and long-term safety of the Breath-O-Correct orthokeratology (OK) lens was evaluated in a 2-year randomized, single vision (SV) spectacle lens-controlled, single-blind clinical trial combining clinical and tear proteomics data. A total of 71 children (43 OK, 9.8 ± 1.3 years; 28 SV, 9.5 ± 1.4 years) completed the 2-year study. Axial length (AL), cycloplegic refraction, clinical safety parameters (best-corrected visual acuity, central cornea thickness, corneal endothelial health, ocular surface disease index), and quantitative tear proteomics were evaluated by masked examiners. Mean 2-year-normalized AL elongations in the OK and SV groups differed significantly (p = 0.03) and were 0.37 ± 0.37 mm and 0.60 ± 0.41 mm, respectively. OK-mediated myopia control efficacy was 37.1%. No significant difference was found in clinical safety parameters of both groups (p > 0.10), except for a thinner central corneal thickness in the OK group (p = 0.01). Proteomics revealed modest OK lens-mediated effects on immune response proteins, including an increased abundance of haptoglobin at 6 and 12 months and a decreased abundance of two proteins (neutrophil defensin 3 and histone 4) at 6 months. The changes were further validated using a high-resolution multiple-reaction monitoring (MRMHR) mass spectrometry. In summary, the Breath-O-Correct OK lens significantly reduced AL elongation in schoolchildren without adverse clinical effects or subclinical inflammatory responses.